Contemporary reoperative mitral valve surgery: technical considerations and clinical outcomes
A Fatehi Hassanabad, M Turcotte, C Dennehy… - …, 2020 - journals.sagepub.com
As patients with cardiac disease live longer, reoperative mitral valve surgery has become
more common. Although these operations are technically challenging and of high risk …
more common. Although these operations are technically challenging and of high risk …
Adverse events following transcatheter edge-to-edge repair (TEER) Using MitraClip: lessons learned from the Manufacturer and User Facility Device Experience …
Abstract Objective The MitraClip from Abbott is FDA approved intracardiac implantable
device for transcatheter edge-to-edge repair (TEER). Despite a few previously published …
device for transcatheter edge-to-edge repair (TEER). Despite a few previously published …
Assessing the Reproducibility of Research Based on the Food and Drug Administration Manufacturer and User Facility Device Experience Data
Objective This article aims to assess the reproducibility of Manufacturer and User Facility
Device Experience (MAUDE) data-driven studies by analyzing the data queries used in their …
Device Experience (MAUDE) data-driven studies by analyzing the data queries used in their …
[HTML][HTML] Postdischarge-to-30-day mortality among patients receiving MitraClip: a systematic review and meta-analysis
Background MitraClip (MC) implantation is the recommended treatment for severe
symptomatic mitral regurgitation in patients not responding to medical therapy and at …
symptomatic mitral regurgitation in patients not responding to medical therapy and at …
[HTML][HTML] Standardised definitions of transcatheter edge-to-edge repair leaflet adverse events: identifying complications or complicating identification?: Standardised …
RT Hahn - EuroIntervention, 2021 - ncbi.nlm.nih.gov
Transcatheter edge-to-edge repair (TEER) is now a class IIa (1) or IIb (2) recommendation
for patients with high surgical risk and patients with severe primary mitral regurgitation (MR) …
for patients with high surgical risk and patients with severe primary mitral regurgitation (MR) …
Death Incidents Following Transcatheter Edge-to-Edge Repair (TEER) With the MitraClip Device: Analysis of 10-years Post-marketing Death Reports from the …
XH Sun, Y Zhao, Y Li - medRxiv, 2024 - medrxiv.org
Objective: The MitraClip device (Abbott), an FDA-approved transcatheter apparatus, is
employed for the management of mitral regurgitation (MR) among patients deemed at high …
employed for the management of mitral regurgitation (MR) among patients deemed at high …
Learning curve and procedural volume in mitral valve disease
M Saccocci, A Colli - Journal of Cardiac Surgery, 2021 - Wiley Online Library
The impact of procedural volume on outcome results is a widespread topic in surgery, The
importance of referral centers and high‐volume hospitals have reached the forefront …
importance of referral centers and high‐volume hospitals have reached the forefront …
Adjunctive use of fluoroscopy during MitraClip implantation reduces procedural complexity: The parallax technique
GD Singh, JH Rogers, S Chen, J Yap… - Catheterization and …, 2021 - Wiley Online Library
Abstract Background During MitraClip implantation sub‐valvular correction of trajectory
and/or alignment may increase adverse clip or leaflet events. With systematic adjunctive use …
and/or alignment may increase adverse clip or leaflet events. With systematic adjunctive use …
Reply: Explaining differing outcomes from the COAPT and MITRA-FR trials using disproportionate and proportionate secondary mitral regurgitation
First, our results should not be considered in contrast to Grayburn's hypothesis. There are
two main explanations for the lack of differences in outcomes of patients with proportionate …
two main explanations for the lack of differences in outcomes of patients with proportionate …
[HTML][HTML] MitraClip Insertion to Hasten Recovery from Severe COVID-19
Discussion The true impact of severe valvular heart disease in patients with COVID-19 has
not described in the literature so far. 3, 9, 10 Nevertheless, it is clear that patients with severe …
not described in the literature so far. 3, 9, 10 Nevertheless, it is clear that patients with severe …